INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$1.75
Market Cap
$46.52M
52W High
$2.16
52W Low
$1.20
ADV30
1,134,501
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
| Sep 2025 | 0 | — | -7,433,000 | -6,472,000 | 33,358,000 | 27,734,000 | 7,980,000 |
| Jun 2025 | 0 | — | -8,057,000 | -24,458,000 | 37,684,000 | 33,374,000 | 8,817,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,582,000
Investing CF
$-336,000
Financing CF
$27,612,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.32
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-209,037,000
Inventory
—
Receivables
$4,541,000
ST Investments
—
EBIT TTM
$-30,869,000
Pretax Income TTM
$-45,933,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-11,248,000
Enterprise Value
$27,207,906
Total Cash
$21,358,000
Total Debt
$1,510,000
Shares Out
26,585,258
Trailing EPS
$-1.63
Book Value
$0.74
ROE
-168.8%
ROA
-52.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | — | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | — | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | — | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | — | -22,686,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| ATYR | aTYR PHARMA INC | $47.62M | $0.49 | — |
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
| TIL | Instil Bio, Inc. | $48.29M | $7.12 | — |
| MGX | Metagenomi Therapeutics, Inc. | $44.80M | $1.19 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
2026-07-31 11:00 · Yahoo
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 11:00 · Yahoo
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
2026-07-30 11:00 · Yahoo
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
2026-07-20 11:00 · Yahoo
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
2026-07-15 11:00 · Yahoo
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
2026-07-09 11:00 · Yahoo
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
2026-07-01 11:00 · Yahoo
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
2026-06-25 11:00 · Yahoo
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
2026-06-23 12:00 · Yahoo
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
2026-06-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.